UNSPSC 51111862: Nilotinib

This classification denotes a tyrosine kinase inhibitor with the molecular formula C28H22F3N7O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F41401512X. European Medicines Agency schedules nilotinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25225. The term NILOTINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, no. 3, 2006, list 56). Most nations schedule nilotinib under HS 29335990 and SITC 51576.

As of Q4 2014, NILOTINIB remains the US FDA Preferred Term for this commodity. Nilotinib bears US NLM identifiers UMLS ID C1721377 and NCI Concept Code C48375. SMILES: CL.FC(F)(F)C1CC(N2CC(NC2)C)CC(NC(=O)C2CC(NC3NC(C4CCCNC4)CCN3)C(CC2)C)C1.O.

UNSPSC 51111862 Nilotinib is a Commodity code designating a branded tyrosine kinase inhibitor pharmaceutical used to treat chronic myeloid leukemia and gastrointestinal stromal tumors. State and local governments procure this drug through health plans, Medicaid programs, and public hospital systems that cover oncology treatment. The product is typically sourced through pharmaceutical wholesalers, group purchasing organizations, or direct manufacturer contracts negotiated at the state or regional health authority level. Procurement bodies include state Medicaid agencies, state health departments managing public hospital networks, county health systems, and municipal hospitals with oncology services.

The most-recent-state-local-contract-opportunities block provided no records for this code. State and local procurement activity under UNSPSC 51111862 is not visible in current opportunity data.